{"product_id":"biolegend-100214","title":"Biolegend, 100214, Pacific Blue™ anti-mouse CD3 Antibody, 100μg","description":"\u003cp\u003eCD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α\/β or γ\/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide\/MHC antigen complex\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: γδTCR-positive T-T hybridoma D1\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The CD3 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Neff T, et al. 2012. Proc Natl Acad Sci U S A. 109:5228. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed Rahman SMT, et al. 2022. Cell Rep. 41:111682. PubMed Li J, et al. 2022. Elife. 11:. PubMed Reynolds MB, et al. 2023. Sci Adv. 9:eade8701. PubMed Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed Wang D, et al. 2022. Cell Rep. 39:110587. PubMed Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed Christian D, et al. 2014. Infect Immun . 82:4056. PubMed Eunju O, et al. 2014. J Virol. 88:7764. PubMed Schneider C, et al. 2018. Cell. 174:271. PubMed Lasso P, et al. 2019. Integr Cancer Ther. 18:1534735419848040. PubMed Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed Mathur S, et al. 2021. JCI Insight. 6:. PubMed Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed Lalla C, et al. 2011. J Immunol. 186:4490. PubMed Zhang X, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:494. PubMed Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed Wang B, et al. 2022. Nat Commun. 13:3821. PubMed Shiomi A, et al. 2014. J Immunol. 193:849. PubMed Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed Ma W, et al. 2017. Sci Rep. . 10.1038\/s41598-017-15661-6. PubMed Koikawa K, et al. 2021. Cell. 184:4753. PubMed Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed Chen S, et al. 2016. Immunol Cell Biol. 10.1038\/icb.2016.11. PubMed Achtman A, et al. 2009. J Leukoc Biol. 85:409. PubMed Sitrin J, et al. 2017. J Immunol. 10.4049\/jimmunol.1700608. PubMed Ma W, et al. 2017. Cell Death \u0026amp; Disease. 10.1038\/cddis.2017.47. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Ullrich L, et al. 2021. Front Immunol. 12:729607. PubMed Nowlan B, et al. 2019. Haematologica. 105:71. PubMed Phalke SP, et al. 2019. PLoS One. 14:e0218827. PubMed Bitschar K, et al. 2019. Nat Commun. 10:2730. PubMed Koh KH, et al. 2019. J Clin Invest. 129:1713. PubMed Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed Li C, et al. 2018. Cell. 174:285. PubMed Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed Baratin M, et al. 2017. Immunity. 47:349. PubMed Wang Z, et al. 2022. NPJ Vaccines. 7:144. PubMed Zheng Y, et al. 2022. J Immunol. 208:501. PubMed Xiao Y, et al. 2021. Cell. 184:6037. PubMed Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed Liu H, et al. 2021. Vaccine. 39:7001. PubMed Wang X, et al. 2018. Elife. 7:. PubMed Chiossone L, et al. 2009. Blood. 113:5488. PubMed Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed Zhang L, et al. 2020. Cell. 442:181. PubMed Luo H, et al. 2019. Cell Rep. 26:945. PubMed Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed García–Rodríguez S, et al. 2018. Sci Rep. 2.664583333. PubMed Doo DW, et al. 2020. Ther Adv Med Oncol. 12:1758835920913798. PubMed Wang X, et al. 2021. Sci Transl Med. 13:. PubMed Chonwerawong M, et al. 2020. Gastroenterology. 159:169. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed\u003cbr\u003e\nRRID: AB_493644 (BioLegend Cat. No. 100213) AB_493645 (BioLegend Cat. No. 100214)\u003cbr\u003e\nStructure: Ig superfamily, CD3\/TCR, 20 kD\u003cbr\u003e\nDistribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells\u003cbr\u003e\nFunction: Antigen recognition, TCR signal transduction, T cell activation\u003cbr\u003e\nLigand\/Receptor: Peptide antigen\/MHC-complex\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.\u003cbr\u003e\nGene ID: 12502\u003cbr\u003e\nUniProt: View information about CD3 on UniProt.org\u003cbr\u003e\nClone: 17A2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T cell antigen receptor complex, T3\u003cbr\u003e\nIsotype: Rat IgG2b, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860822511785,"sku":"100214","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-100214","provider":"Iright","version":"1.0","type":"link"}